



Press Release

Friday, June 6, 2014

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

Strides Arcolab receives US FDA approval for Methoxsalen Softgel Capsules

Niche Product to be launched immediately

June 6, 2014: Strides Arcolab (BSE: 532531, NSE: STAR) today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Methoxsalen Capsules USP, 10 mg (Soft Gelatin Capsules)**.

According to IMS data, the US market for generic Methoxsalen Capsule is approximately USD 13.6 Million, with no generic player.

The product will be manufactured at the Company's USFDA approved Oral dosage facility at Bangalore and marketed directly by Strides in the US Market.

About Methoxsalen Capsules



Methoxsalen is a drug used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, clearing up the disease.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mohan Kumar, CEO – Pharma +91 80 6784 0748	Weber Shandwick
Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745	Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com
	Mahesh Nair: +91 98803 76648 MNair@webershandwick.com

